Numab Therapeutics and Ono Pharmaceutical Join Forces for the Development of NM49 for Treating Cancer
Shots:
- Numab and Ono Pharmaceutical have signed an option and collaboration agreement for the development and commercialization of the former’s NM49 for treating cancer
- As per the agreement, Ono gains an option to globally in-license NM49 to develop & commercialize it before initiating a P-III trial while Numab retains the option to co-develop and commercialize in the US, with eligibility for co-promotion and a 50/50 profit split upon exercising the option
- Numab is entitled to receive an undisclosed upfront payment, development, regulatory & sales-based milestone payments plus tiered net-sales-based royalties and will carry out preclinical studies and CMC activities, with Ono bearing the expenses if the program enters clinical development
Ref: Numab | Image: Numab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
